M
Ming Yin
Researcher at Genentech
Publications - 5
Citations - 1105
Ming Yin is an academic researcher from Genentech. The author has contributed to research in topics: Vemurafenib & Cobimetinib. The author has an hindex of 5, co-authored 5 publications receiving 1048 citations.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A. McArthur,Paul B. Chapman,Caroline Robert,James Larkin,John B. A. G. Haanen,Reinhard Dummer,Antoni Ribas,David Hogg,Omid Hamid,Paolo A. Ascierto,Claus Garbe,Alessandro Testori,Michele Maio,Paul Lorigan,C. Lebbé,Thomas Jouary,Dirk Schadendorf,Stephen J O'Day,John M. Kirkwood,Alexander M.M. Eggermont,Brigitte Dréno,Jeffrey A. Sosman,Keith T. Flaherty,Ming Yin,Ivor Caro,Suzanne Cheng,Kerstin Trunzer,Axel Hauschild +27 more
TL;DR: An extended follow-up analysis of the total population and in the BRAF(V600E) and BRAF (V600K) mutation subgroups is presented, finding that overall survival and progression-free survival was significantly longer in the vemurafenib group than in the dacarbazine group.
Journal ArticleDOI
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
Antoni Ribas,Rene Gonzalez,Anna C. Pavlick,Omid Hamid,Thomas F. Gajewski,Adil Daud,Lawrence E. Flaherty,Theodore F. Logan,Bartosz Chmielowski,Karl D. Lewis,Damien Kee,Peter D. Boasberg,Ming Yin,Iris T. Chan,Luna Musib,Nicholas Choong,Igor Puzanov,Grant A. McArthur +17 more
TL;DR: The combination of vemurafenib and cobimetinib was safe and tolerable when administered at the respective maximum tolerated doses, and has promising antitumour activity.
mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A. McArthur,Paul B. Chapman,Caroline Robert,James Larkin,John B. A. G. Haanen,Reinhard Dummer,Antoni Ribas,David Hogg,Omid Hamid,Claus Garbe,Alessandro Testori,Michele Maio,Paul Lorigan,Céleste Lebbé,Thomas Jouary,Dirk Schadendorf,John M. Kirkwood,Ming Yin,Ivor Caro,Suzanne Cheng,Kerstin Trunzer,Axel Hauschild +21 more
TL;DR: Overall survival and progression-free survival were significantly longer in the vemurafenib group than in the dacarbazine group, and the most frequent grade 3-4 events were cutaneous squamous-cell carcinoma and keratoacanthomas.
Journal ArticleDOI
Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7).
Igor Puzanov,Grant A. McArthur,Rene Gonzalez,Anna C. Pavlick,Omid Hamid,Thomas F. Gajewski,Ming Yin,Jill Fredrickson,Nicholas Choong,Antoni Ribas +9 more
TL;DR: reported fewer AEs compared to BRAFi-naive pts, and most common AEs were non-acneiform rash, diarrhea, photosensitivity/sunburn, fatigue and liver test abnormality.
Journal ArticleDOI
Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.
Grant A. McArthur,Jason Callahan,Antoni Ribas,Rene Gonzalez,Anna C. Pavlick,Omid Hamid,Thomas F. Gajewski,Igor Puzanov,Adil Daud,Ming Yin,Nicholas Choong,Jinay K Shah,Jill Fredrickson,Rodney J. Hicks +13 more
TL;DR: FDG-PET response is evaluated as predictor of clinical outcome in BRAFi/MEKi naive patients treated with this combination, and maximum standardized uptake value (SUVmax) in up to 5 target lesions, as an indicator of metabolism.